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Impact of Type 2 Myocardial Infarction (MI) on Hospital-Level MI
Outcomes: Implications for Quality and Public Reporting
Sameer Arora, MD; Paula D. Strassle, MSPH; Arman Qamar, MD; Evan N. Wheeler, BS; Alexandra L. Levine, BS; Jacob A. Misenheimer, MD;
Matthew A. Cavender, MD, MPH; George A. Stouffer, MD; Prashant Kaul, MD
Background-—The International Classiﬁcation of Diseases (ICD) coding system does not recognize type 2 myocardial infarction (MI)
as a separate entity; therefore, patients with type 2 MI continue to be categorized under the general umbrella of non–ST-segment–
elevation myocardial infarction (NSTEMI). We aim to evaluate the impact of type 2 MI on hospital-level NSTEMI metrics and discuss
the implications for quality and public reporting.
Methods and Results-—We conducted a single-center retrospective analysis of 1318 patients discharged with a diagnosis of
NSTEMI between July 2013 and October 2014. The Third Universal Deﬁnition was used to deﬁne type 1 and type 2 MI. Weighted
Kaplan–Meier curves were used to analyze risk of mortality and readmission. Overall, 1039 patients met NSTEMI criteria per the
Third Universal Deﬁnition; of those, 264 (25.4%) had type 2 MI. Patients with type 2 MI were older, were more likely to have chronic
kidney disease, and had lower peak troponin levels. Compared with type 1 MI patients, those with type 2 MI had higher inpatient
mortality (17.4% versus 4.7%, P<0.0001) and were more likely to die from noncardiovascular causes (71.7% versus 25.0%,
P<0.0001). Despite weighting for patient characteristics and discharge medications, patients with type 2 MI had higher mortality at
both 30 days (risk ratio: 3.63; 95% conﬁdence interval, 1.67–7.88) and 1 year (risk ratio: 1.98; 95% conﬁdence interval, 1.44–2.73)
after discharge. Type 2 MI was also associated with a lower 30-day cardiovascular-related readmission (risk ratio: 0.49; 95%
conﬁdence interval, 0.12–2.06).
Conclusions-—NSTEMI metrics are signiﬁcantly affected by type 2 MI patients. Type 2 MI patients have distinct etiologies, are
managed differently, and have higher mortality compared with patients with type 1 MI. Moving forward, it may be appropriate to
exclude type 2 MI data from NSTEMI quality metrics. ( J Am Heart Assoc. 2018;7:e008661. DOI: 10.1161/JAHA.118.008661.)
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I n 2007, the European Society of Cardiology, AmericanCollege of Cardiology, American Heart Association, and
World Heart Federation task force released an expert
consensus document redeﬁning myocardial infarction (MI)
into 5 types.1 Given the increased sensitivity of biomarker
assays, the Third Universal Deﬁnition of MI was published in
2012.2 Type 1 MI was referred to as acute coronary syndrome
(ACS) caused by atherosclerotic plaque rupture, ulceration,
ﬁssure, or erosion leading to intraluminal thrombus formation
and obstructed coronary blood ﬂow. Type 2 MI was deﬁned as
MI not caused by plaque rupture but secondary to an
imbalance between myocardial oxygen demand and supply
related to an underlying cause. Type 3 MI is deﬁned as cardiac
death due to MI, and types 4 and 5 are MI associated with
revascularization procedures.
Type 2 MI is common and has been associated with worse
prognosis.3–6 Although there has been widespread accep-
tance of the concept of type 2 MI, the current International
Classiﬁcation of Diseases (ICD) coding system does not
recognize type 2 MI as a separate entity; therefore, its impact
on hospital-level MI outcomes has not been studied because
these patients continue to be categorized under the general
umbrella of non–ST-segment–elevation myocardial infarction
(NSTEMI). Compounding this is the fact that guidelines-based
post-ACS treatment is expected to be followed in all patients
with a diagnosis of MI. Although aspirin, statins, and beta
blockers may have a role in the management of some patients
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with type 2 MI, using guideline-based ACS therapy in every
case of type 2 MI may be inappropriate. The purpose of this
study, therefore, was to assess differences in patient
characteristics, treatment, mortality, and hospital readmis-
sions between type 2 and type 1 MI patients and to evaluate
their potential impact on hospital-level MI metrics and
implications for quality and public reporting.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Patient Identiﬁcation
Chart review was performed on consecutive patients dis-
charged from a single healthcare center between July 1, 2013,
and October 31, 2014, with International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
code 410 (acute MI) at discharge. The requirement of patients
to give informed consent was waived, and the study was
approved by the institutional review board. All charts were
reviewed, including admission notes, cardiology consultation
notes, discharge summaries, and other notes relevant to
abstract demographics and comorbidities, including age, sex,
history of hypertension, diabetes mellitus, hyperlipidemia,
tobacco abuse (current or remote), history of percutaneous
coronary intervention, history of coronary artery bypass
grafting, peripheral artery disease, chronic kidney disease,
and body mass index (BMI). Clinical variables collected were
chief complaint at presentation, primary diagnosis at admis-
sion, initial and peak cardiac troponin I (cTnI), ischemic ECG
changes (ST-segment depression, T-wave inversion, and new
left bundle-branch block), echocardiographic data from stud-
ied hospitalization, coronary angiographic ﬁndings including
details of intervention, and discharge medications restricted
to aspirin, statin, beta blocker, and P2Y12 inhibitors.
Patients were excluded if they (1) were discharged with a
diagnosis of ST-segment–elevation MI; (2) did not meet the
biomarker criteria of the universal deﬁnition; (3) were
transferred to our facility from another facility, to prevent
any discrepancy between different types of troponins used at
different facilities; (4) did not have troponins measured within
24 hours of admission; or (5) presented with cardiac arrest in
the emergency department. In patients who were readmitted,
the earlier hospitalization was indexed to prevent duplication
of patients. Each patient was classiﬁed as type 1 or type 2 MI
using the Third Universal deﬁnition of MI2 criteria.
Type 1 MI
Detection of fall or rise of troponin with at least 1 value >99th
percentile marked by the manufacturer. A 20% increase or
decrease in the value of cTnI was marked as the threshold to
meet the biomarker criteria (when initial cTnI was ≥0.5 ng/
mL). In case the initial cTnI was close to 99th percentile
(0.045–0.5 ng/mL), at least ≥3-SD change (≥30% change)
was required.7 If the biomarker criteria were met, one of the
following additional criteria had to be satisﬁed: (1) symptoms
suggestive of ischemia, (2) new or presumed ST-T wave
changes or left bundle-branch block, (3) development of
pathological Q waves in the ECG, (4) intracoronary thrombus
noted on coronary angiography or autopsy, (5) new wall
motion abnormality noted on echocardiography.
Type 2 MI
Fulﬁllment of criteria for type 1 MI as described, along with
identiﬁcation of an alternative (noncoronary) explanation
known to cause a supply/demand mismatch either by
decreasing myocardial oxygen supply or by increasing
myocardial oxygen demand. The “condition other than
coronary artery disease contributing to an imbalance between
myocardial oxygen supply and/or demand” was deﬁned as an
alternate factor. The presence of an underlying alternate
Clinical Perspective
What Is New?
• In current US clinical practice, type 2 myocardial infarction
(MI) patients are grouped under the general umbrella of
non–ST-segment–elevation myocardial infarction (NSTEMI).
• Understanding the impact of type 2 MI on overall NSTEMI
outcomes is crucial.
• Our results show that type 2 MI has signiﬁcantly higher
mortality than plaque-rupture type 1 MI and has a signiﬁcant
impact on overall NSTEMI mortality.
• Patients with type 2 MI are discharged less frequently on
medications, part of acute coronary syndrome core mea-
sures, which may affect the overall rates at which patients
are discharged on these medications in an NSTEMI
population.
What Are the Clinical Implications?
• Type 2 MI may skew MI metrics at different institutions,
which could lead to inaccurate assessment of quality and
performance measures by MI quality review programs; if
assessments are based on patient populations that the
metrics were not designed for, a result could be inappro-
priate penalties for healthcare providers.
• Moving forward, it seems prudent to categorize type 2 MI
patients separately, instead of under the general umbrella of
NSTEMI, and to exclude these patients from acute MI quality
metrics.
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factor known to induce a supply/demand mismatch was
required for a diagnosis of type 2 MI to be considered along
with fulﬁllment of criteria of MI, as per the Third Universal
Deﬁnition of MI.
Biomarker Criteria
The 99th percentile of the reference range for cTnI (Siemens
Healthcare Diagnostics) used at our institution was deter-
mined to be 0.045 ng/mL, and a coefﬁcient of variance <10%
was estimated to be <0.04 ng/mL. A value >0.045 ng/mL
was an initial requisite, along with a rise or fall pattern, as
deﬁned by the universal deﬁnition. Samples of cTnI were
drawn during clinical care. Peak troponin levels were deﬁned
as the highest troponin level obtained during the hospitaliza-
tion course, regardless of the number of values obtained.
Statistical Analyses
Patient characteristics, comorbidities, and ACS core measure
medications (aspirin, statins, and beta blockers) prescribed at
discharge were compared using v2 and Wilcoxon–Mann–
Whitney tests, as appropriate. P<0.05 was considered
statistically signiﬁcant. A Wilcoxon–Mann–Whitney test was
also used to assess differences in peak troponin levels
between type 1 and type 2 MI.
Mortality
Among patients who died during their hospitalization, the
death summary from medical records was used to evaluate
the cause of death, which was categorized as cardiovascular8
and noncardiovascular causes. Both overall inpatient mortal-
ity and noncardiovascular related inpatient mortality were
compared for type 1 and type 2 MI patients, using
multivariable logistic regression after adjusting for confound-
ing factors.
Kaplan–Meier survival curves were used to estimate the
30-day and 1-year risk of mortality after discharge among
patients with type 1 and type 2 MI. Both risk differences and
risk ratios (RRs) were calculated. Follow-up mortality data
were obtained by searching for the date of birth for each
patient in the North Carolina State Center for Health Statistics
and conﬁrmed using the name and sex of each patient. To
prevent missing death records, mortality was cross-checked
by searching for the name and then conﬁrming the date of
birth for each patient. This strategy helped us detect a few
patients (1–2%) who had either the wrong date of birth
listed or the name incorrectly spelled in the medical record or
the mortality database. Follow-up time for each patient was
calculated by counting the number of days between their
discharge and date of death. If no death date was found, the
patient was assumed to be alive and to have 365 days of
follow-up. Patients who died during their inpatient hospital-
ization were excluded from all survival analyses.
Weighted Kaplan–Meier curves were used to estimate the
standardized cumulative 30-day and 1-year risk of mortality
after discharge.9 Standardized estimates were weighted
using inverse probability of treatment weights to account for
potential confounding by weighting patients so that the
exposure is effectively randomized across the included
covariates. Brieﬂy, the inverse probability of treatment
weight for each patient was estimated using multivariable
logistic regression that modeled the probability of having
type 2 MI, compared with type 1, using patient age, sex,
BMI, hypertension, diabetes mellitus, hyperlipidemia, periph-
eral artery disease, chronic kidney disease, smoking status
(current or remote), previous percutaneous coronary inter-
vention, and previous coronary artery bypass grafting and
whether aspirin, statins, or beta-blockers were prescribed at
discharge. Both age and BMI were modeled as restricted
cubic splines to allow for the most ﬂexibility in the
continuous variables. Weights were stabilized using the
marginal (ie, overall) probability of having a type 2 MI in the
cohort. Forty-one patients (4.3%) were missing BMI and/or
discharge medication data and thus were excluded from all
standardized analyses.
Thirty-Day Readmission
The 30-day readmission data, including primary discharge
diagnosis code, were obtained from the cardiac quality
committee by linking the account numbers from the original
MI hospitalization and subsequent readmissions within
30 days following discharge. Readmissions were further
categorized into cardiovascular (deﬁned as a readmission
related to MI, congestive heart failure, cerebrovascular
accident, cardiac arrhythmia, cardiac device complication, or
structural heart abnormality) and noncardiovascular causes.
Similar to mortality, Kaplan–Meier survival curves were used
to estimate the standardized 30-day risk of any readmission
and cardiovascular-related readmission among patients dis-
charged alive. Death was treated as a competing risk using an
Aalen–Johansen estimator in all readmission analyses.
Weighted survival curves, using the same inverse probability
of treatment weight models described earlier, were used to
estimate the standardized risk of any readmission and
cardiovascular readmission.
Conﬁdence intervals (CIs) for both the crude and stan-
dardized cumulative incidence of mortality and readmission
were calculated using the standard deviation estimated from
nonparametric bootstrapping. Speciﬁcally, 500 resamples
with replacement were conducted, and the risk difference
and RR were calculated using the procedures outlined above,
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and the standard deviation from the resamples was calcu-
lated.
All analyses were performed using SAS 9.4 (SAS Institute).
Results
A total of 1727 consecutive hospitalizations were coded as
acute MI, including 299 hospitalizations for ST-segment–
elevation MI. After application of inclusion criteria, 1039
patients were included in the ﬁnal analysis (Figure 1). Patients
with cardiac arrest were excluded. We did not identify any
patients meeting the deﬁnition of type 4 or type 5 MI. Of 1039
patients, 775 (74.6%) were classiﬁed as having type 1 MI and
264 (25.4%) were classiﬁed as having type 2 MI. Patients with
type 2 MI were older (73 versus 65 years, P<0.0001), less
likely to have hyperlipidemia (50.0% versus 57.1%, P=0.05),
more likely to have chronic kidney disease (25.2% versus
16.8%, P=0.003), less likely to smoke (30% versus 42%,
P=0.0006), and had lower BMI (26 versus 29, P<0.0001)
compared with patients with type 1 MI (Table 1). Patients with
type 2 MI were also less likely to undergo coronary
angiography (25.8% versus 78.6%, P<0.0001), percutaneous
coronary intervention (12.1% versus 46.8%, P<0.0001), and
coronary artery bypass grafting (1.5% versus 11.7%,
P<0.0001). No other signiﬁcant differences in clinical char-
acteristics were observed.
The median peak troponin levels for patients with type 1 MI
(2.5 ng/mL; interquartile range: 0.7–10.0 ng/mL) was sig-
niﬁcantly higher than the median peak troponin levels for
patients with type 2 MI (1.6 ng/mL; interquartile range: 0.5–
3.7 ng/mL), P<0.0001 (Figure 2). The nonischemic triggers
for type 2 MI (alternate factors) included infection or sepsis
(28.0%), respiratory failure (17.8%), congestive heart failure
(10.6%), hypertension (7.2%), and anemia (7.2%; Figure 3). The
median length of stay was shorter for patients with type 1
compared with type 2 MI (4 days [interquartile range: 2–8]
versus 7 days [interquartile range: 4–14], P<0.0001).
Overall. 82 patients (7.9%) died during their index hospi-
talization. Patients with type 2 MI were more likely to die than
those with type 1 MI (17.4% versus 4.7%, P<0.0001). Patients
Figure 1. Consortium selection diagram for inclusion in the ﬁnal analysis. ICD-9-CM indicates
International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation; MI, myocardial infarction;
NSTEMI, non–ST-segment–elevation myocardial infarction; STEMI, ST-segment–elevation myocardial
infarction.
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with type 2 MI were also more likely to die from noncardio-
vascular causes (71.7% versus 25.0%, P<0.0001; Figure 4).
Speciﬁcally, among type 1 MI patients, 23 (63.9%) died from
MI, 8 (22.2%) died from infection or sepsis, 2 (5.6%) died from
cardiac arrhythmias, 1 (2.8%) died from congestive heart
failure, 1 (2.8%) died from stroke, and 1 (2.8%) died from
respiratory failure. In comparison, among patients with type 2
MI, 23 (50.0%) died from infection or sepsis, 5 (10.9%) died
from sudden cardiac death, 4 (8.7%) died from stroke, 4 (8.7%)
died from cancer, 3 (6.5%) died from respiratory failure, 3
(6.5%) died from congestive heart failure, 2 (4.4%) died from
gastrointestinal bleeds, 1 (2.2%) died from cardiac arrhythmia,
and 1 (2.2%) died from cervical injury. Even after adjusting for
patient demographics and comorbidities, type 2 MI was still
signiﬁcantly associated with increased odds of inpatient
mortality (adjusted odds ratio: 3.76; 95% CI, 2.24–6.29) and
noncardiovascular causes (adjusted odds ratio: 6.47; 95% CI,
1.74–23.99).
Medication data were available for 98.4% of patients
discharged alive (n=942). Although the majority of patients
Table 1. Patient Characteristics Stratiﬁed by Type of MI
MI Type 1
(n=775)
MI Type 2
(n=264) P Value
Age, y,
median (IQR)
65 (55–76) 73 (64–81) <0.0001
Male sex, n (%) 434 (56) 127 (48) 0.03
BMI, kg/m2,
median (IQR)
29 (25–35) 26 (23–31) <0.0001
Hypertension, n (%) 642 (83) 225 (86) 0.27
Diabetes mellitus, n (%) 371 (48) 110 (42) 0.09
Hyperlipidemia,
n (%)
441 (57) 131 (50) 0.05
PAD, n (%) 111 (14) 46 (18) 0.21
CKD, n (%) 130 (17) 66 (25) 0.003
Smoker, n (%) 327 (42) 80 (30) 0.0006
Previous PCI, n (%) 209 (27) 56 (21) 0.07
Previous CABG,
n (%)
112 (15) 51 (19) 0.06
Ejection fraction, %,
median (IQR)
55 (40–55) 53 (38–55) 0.05
Ischemic ECG,
n (%)*
369 (48) 120 (45) 0.48
Initial troponin,
ng/mL,
median (IQR)
0.33 (0.33–1.34) 0.36 (0.10–1.16) 0.57
Initial troponin, n (%)
1–2.99 URL† 270 (35) 79 (30) 0.15
3–4.99 URL 78 (10) 33 (13) 0.30
≥59 URL 425 (55) 152 (58) 0.47
Peak troponin,
ng/mL,
median (IQR)
2.53 (0.66–10.00) 1.57 (0.48–3.72) <0.0001
Peak troponin, n (%)
1–2.99 URL 48 (6) 19 (7) 0.56
3–4.99 URL 34 (4) 17 (6) 0.19
≥59 URL 693 (89) 228 (86) 0.18
Procedures during index hospitalization
Coronary
angiography,
n (%)
609 (79) 68 (26) <0.0001
PCI, n (%) 363 (47) 32 (12) <0.0001
CABG, n (%) 91 (12) 4 (2) <0.0001
Medications on discharge‡
Aspirin, n (%) 637 (87) 154 (73) <0.0001
Statin, n (%) 646 (89) 153 (72) <0.0001
Beta blocker, n (%) 645 (88) 165 (78) 0.0001
P2Y12 platelet
inhibitor, n (%)
430 (59) 72 (34) <0.0001
Continued
Table 1. Continued
MI Type 1
(n=775)
MI Type 2
(n=264) P Value
Number of
medications,
median (IQR)
3 (2–3) 2 (2–3) <0.0001
BMI indicates body mass index; CABG, coronary artery bypass grafting; CKD, chronic
kidney disease; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral
arterial disease; PCI, percutaneous coronary intervention; URL, upper reference limit.
*Ischemic ECG changes were deﬁned as (1) new ST-T wave changes, (2) new left bundle-
branch block, and (3) new Q waves. In cases of unknown baseline ECG, abnormality was
assumed to be new.
†Upper reference of our assay (cardiac troponin I) was 0.045 ng/mL.
‡Among patients alive at discharge, n=957; 10 type 1 MI patients and 7 type 2 MI
patients were missing medication data; documented contraindication was not taken into
consideration to assess medication use rates.
Figure 2. Distribution of peak troponin levels for patients with
type 1 MI (red line) and type 2 MI (blue line). MI indicates
myocardial infarction.
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were discharged on multiple medications, patients with type
1 MI were more likely to be discharged on aspirin (87.4%
versus 72.6%, P<0.0001), statins (88.5% versus 72.2%,
P<0.0001), and beta blockers (88.4% versus 77.8%,
P=0.0001) compared with patients with type 2 MI (Table 1).
Patients with type 1 MI were also more likely to be
discharged on P2Y12 platelet inhibitors (59.0% versus 34.1%,
P<0.0001).
Patients with type 2 MI were also signiﬁcantly more likely
to die within 30 days after discharge (11.9% versus 2.2%,
P<0.0001) and 1 year after discharge (34.9% versus 12.4%,
P<0.0001; Figure 5). Patients with type 2 MI were 5 times
more likely to die within 30 days of hospital discharge (RR:
5.50; 95% CI, 2.73–11.08) and almost 3 times more likely to
die within 1 year (RR: 2.80; 95% CI, 2.13–3.67; Table 2). After
weighting for patient demographics, comorbidities, and med-
ications prescribed at discharge, the patients with type 2 MI
were still almost 4 times more likely to die within 30 days
after discharge (RR: 3.63; 95% CI, 1.67–7.88) and 2 times
more likely to die within 1 year (RR: 1.98; 95% CI, 1.44–2.73)
compared with patients with type 1 MI (Table 2). Although
patients with type 2 MI made up only 25.4% of our patient
population, they constituted 56.1% of all NSTEMI patients who
died during hospitalization, 61.9% of those who died within
30 days after discharge, and 45.2% of those who died within
1 year after discharge.
Overall, 90 patients (9.4%) were readmitted within 30 days
of discharge. Among patients with type 1 MI, there were 79
readmissions (10.7%), with 46 readmissions resulting from a
cardiovascular cause. Speciﬁcally, 28 patients (35.3%) were
admitted with MI, 11 (13.9%) for congestive heart failure, 3
(3.8%) for device complications, 2 (2.5%) for stroke, 1 (1.3%)
for cardiac arrhythmia, and 1 (1.3%) for a structural heart
abnormality. Only 11 patients (5.1%) with type 2 MI were
readmitted; of those, 3 (27.3%) were readmitted for conges-
tive heart failure, 1 (9.1%) for MI, and 7 (63.6%) for
noncardiovascular reasons. Both before and after weighting,
readmission rates were lower for type 2 MI compared with
patients with type 1 MI (RR: 0.48; 95% CI, 0.26–0.88) and (RR:
0.57; 95% CI, 0.28–1.16; Table 3, Figure 6). Similarly,
patients with type 2 MI were less likely to be readmitted for
cardiovascular reasons (Table 3).
Discussion
We analyzed data from 1039 consecutive patients with a
discharge diagnosis of NSTEMI and found type 2 MI to be
present in about a quarter of the patients discharged with
Figure 3. Prevalence of alternative factors in patients with type 2 myocardial infarction.
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NSTEMI. Patients with type 2 MI had signiﬁcantly higher
mortality than those with type 1 MI during hospitalization and
at 30 days and 1 year after discharge. During hospitalization,
patients with type 2 MI had lower median peak troponin
levels, and most deaths were noncardiovascular. Patients with
type 2 MI were older and more often female but less likely to
have traditional coronary risk factors such as diabetes
mellitus and hypertension compared with patients with type
1 MI. Patients with type 2 MI were less likely to undergo
cardiac catheterization and revascularization and less likely to
be discharged on medications that are part of post-ACS care.
Despite that, patients with type 2 MI were less likely to be
readmitted, both overall and for cardiovascular causes within
30 days of discharge.
Although deaths secondary to type 1 MI have plateaued in
the past decade, clinical outcomes with type 2 MI vary widely.
In our study, patients with type 2 MI composed 25% of all
NSTEMI patients but represented roughly half of all deaths.
Frequently used risk scores such as the TIMI (Thrombolysis in
Myocardial Infarction) and GRACE (Global Registration of
Acute Coronary Events) models were developed from a cohort
of patients with type 1 MI, and their applicability to type 2 MI
is not known.7 Moreover, studies showing that the degree of
biomarker elevation correlates with adverse cardiovascular
outcomes were also performed in patients with type 1 MI.10–12
Despite higher all-cause mortality, we found signiﬁcantly
lower peak troponin levels and lower prevalence of traditional
coronary risk factors in the type 2 MI group. The fact that
more than two-thirds of all inpatient deaths in patients with
type 2 MI were due to noncardiovascular causes suggests
that mortality in these patients may not be estimated using
traditional approaches.
The most likely reason for the higher mortality observed
with type 2 MI is the presence of an alternate factor
responsible for demand/supply mismatch. In our study, >70%
of the deaths in the type 2 MI cohort were from noncardio-
vascular causes, compared with only a quarter of the deaths
in the type 1 MI cohort. This suggests that although these
alternate factors have potential to cause demand/supply
mismatch leading to type 2 MI, the mortality among these
patients is not secondary to a cardiac process but rather
driven by their primary disease process, such as sepsis and
other noncardiovascular causes. Troponin elevation in heart
failure has been attributed to small vessel obstruction and
endothelial dysfunction.13 Troponin elevation in stroke
patients may occur related to myocardial stretch, endothelial
dysfunction, microvascular spasm, cytokine-mediated
myocardial injury, or catecholamine-mediated myocardial
toxicity.14,15 Compared with stroke, demand/supply mis-
match in seizures has been largely attributed to massive
catecholamine release related to muscular activity, leading to
an elevation in heart rate, blood pressure, and contractility.16
Figure 4. Comparison of causes of mortality between type 1 and type 2 MI. CV indicates
cardiovascular; MI, myocardial infarction.
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A similar mechanism has been attributed to causing neuro-
cardiogenic injury in intracranial hemorrhage.17,18 The under-
lying mechanism of cardiac injury in sepsis continues to be
investigated. Although sepsis is known to cause increased
coronary blood ﬂow,19 it also has been linked to improper
oxygen utilization.20 Other mechanisms such as upregulation
of endothelin 1 have also been demonstrated to play a role in
these patients and could be the trigger for endothelial
dysfunction.21 Furthermore, an increase in cardiac myocyte
permeability in septic patients may also play a role in troponin
leakage.22 Elevated levels of troponins in critical illness or
after surgery can be caused by increased levels of both
endogenous or exogenous catecholamines.23
A second potential explanation for the higher mortality in
patients with type 2 MI are the differences in demographics
and comorbidities. Patients with type 2 MI are older, are more
often female, and have a higher prevalence of chronic kidney
disease. However, even after accounting for patient demo-
graphics and comorbidities, type 2 MI patients still had
signiﬁcantly increased mortality in our analysis. A third
potential explanation is the less frequent use of coronary
angiography and revascularization in type 2 MI. Although we
were not able to categorize postdischarge mortality into
cardiovascular and noncardiovascular causes, almost all of
the type 2 MI patients were readmitted at our institution for
noncardiovascular reasons.
There remains some debate regarding the management of
patients with type 2 MI. The current ICD coding system does
not recognize type 2 MI as a separate entity and continues to
group these patients under the general umbrella of NSTEMI.
This leads to enforcement of guidelines that are part of post-
ACS care for all patients with type 2 MI. Although aspirin,
statin, and beta blockers may have a role in the management
of some patients with type 2 MI,7 using guideline-based ACS
therapy in every patient with type 2 MI may be inappropriate
and could result in adverse events. In our analysis, type 2 MI
patients were discharged with guideline-based ACS therapy at
signiﬁcantly lower levels than type 1 MI patients. In our study,
the rates of guideline-based ACS therapies at discharge for
the type 1 MI group were slightly lower compared with the
real-world utilization reports from the ACTION Registry largely
because we did not exclude patients with a documented
contraindication to these medications from the total number
of patients.24 Despite a lower rate of guideline-based
therapies at discharge, the 30-day readmissions for MI were
lower in the type 2 MI group. Although we treated mortality
after discharge as a competing risk, we were unable to
incorporate inpatient mortality into these models (because
discharge medication usage was missing for these patients). It
is possible that the higher inpatient mortality in type 2 MI
patients contributed to us ﬁnding a lower 30-day readmission
risk in this analysis.
Little is known about the optimal management of type 2
MI, emphasizing the importance of better delineating type 2
MI from type 1 MI, as the optimal management of the 2
groups is likely different. In addition, if they are not
appropriately differentiated, MI metrics at different institu-
tions may be skewed and could lead to inaccurate assess-
ment of quality and performance measures by MI quality
review programs, based on patient populations for which the
Figure 5. Standardized 1-year cumulative risk of mortality after
hospital discharge among patients with type 1 MI (red line) and
type 2 MI (blue line). MI indicates myocardial infarction.
Table 2. Crude and Standardized Risk of Mortality After
Hospital Discharge Stratiﬁed by MI Type Among Patients
Admitted With NSTEMI
Mortality, %
RD 95% CI* RR 95% CI*
Type 2
MI
Type 1
MI
Crude
30-day 11.9 2.2 0.10 0.05–0.14 5.50 2.73–11.08
1-year 34.8 12.4 0.22 0.15–0.29 2.80 2.13–3.67
Standardized†
30-day 8.1 2.2 0.06 0.02–0.10 3.63 1.67–7.88
1-year 25.9 13.1 0.13 0.06–0.20 1.98 1.44–2.73
CI indicates conﬁdence interval; MI, myocardial infarction; NSTEMI, non–ST-segment–
elevation myocardial infarction; RD, risk difference; RR, risk ratio.
*CIs were determined using the standard deviation estimated from 500 nonparametric
bootstrap resamples.
†Standardized for patient age, sex, body mass index, hypertension, diabetes mellitus,
hyperlipidemia, peripheral vascular disease, chronic kidney disease, smoking status,
previous percutaneous coronary intervention, previous coronary artery bypass grafting,
and whether aspirin, statins, or beta blockers were prescribed at discharge.
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metrics were not designed, and inappropriate penalties for
healthcare providers. Moreover, in most research on NSTEMI,
including randomized trials and observational studies, NSTEMI
patients are grouped as 1 cohort and type 2 MI is not isolated
from the population. This approach is likely to have a major
impact on the way the end points are assessed because
outcomes can be skewed against the group with a higher type
2 MI percentage in the NSTEMI cohort. This issue needs to be
further investigated.
Data from the SWEDEHEART (Swedish Web System for
Enhancement and Development of Evidence-Based Care in
Heart Disease Evaluated According to Recommended Thera-
pies) registry found higher crude mortality in patients with
type 2 MI, compared with type 1 MI, that attenuated after
adjustment for demographics, comorbidities, and treatment.3
In contrast, we used the Third Universal Deﬁnition to
distinguish between type 1 and type 2 MI and to provide
additional morbidity data by comparing their inﬂuence on
rehospitalizations. Gaggin et al used the Third Universal
Deﬁnition to distinguish between type 1 and type 2 MI;
however, they limited their study to those undergoing
coronary or peripheral angiography.4 We used ICD-9 codes
to deﬁne NSTEMI patients, regardless of whether they
underwent angiography, and thus were able to evaluate the
effect of type 2 MI on hospital-level MI metrics. Smilowitz
et al attempted to distinguish type 2 MI using the Third
Universal Deﬁnition; however, their study was limited to a
comparison between type 2 MI and myocardial injury.5 In a
recently published study, Neumann et al enrolled 1548
patients (188 with type 1 MI and 99 with type 2 MI) who
presented with suspected MI and used the Third Universal
Deﬁnition to distinguish type 1 from type 2 MI.6 In contrast to
our study, the investigators found no mortality difference
between type 1 and type 2 MI, likely because their analysis
was limited to patients with suspected MI. In addition, fewer
type 1 and type 2 MI patients were included in the study.6
Limitations
The single-center nature of our study may limit the general-
izability of our ﬁndings; however, this allowed us to use the
Third Universal Deﬁnition of MI as a stringent inclusion
criterion. Reliance on ICD coding for NSTEMI at discharge may
have led to some selection bias. We were able to observe only
prescribed medications at discharge; therefore, we assumed
Figure 6. Standardized 30-day cumulative risk of any hospital
readmission (solid) and cardiovascular readmission (dashed) after
discharge, among patients with type 1 MI (red line) and type 2 MI
(blue line). MI indicates myocardial infarction.
Table 3. Crude and Standardized Risk of 30-Day Readmission After Hospital Discharge, Stratiﬁed By MI Type Among Patients
Admitted With NSTEMI
Readmission, %
RD 95% CI* RR 95% CI*Type 2 MI Type 1 MI
Any readmission
Crude 5.0 10.6 0.06 0.09 to 0.02 0.48 0.26–0.88
Standardized† 5.8 10.2 0.04 0.09 to 0.00 0.57 0.28–1.16
Cardiovascular‡ readmission
Crude 1.8 6.1 0.04 0.06 to 0.02 0.30 0.11–0.86
Standardized† 2.9 5.9 0.03 0.07 to 0.01 0.49 0.12–2.06
CI indicates conﬁdence interval; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; RD, risk difference; RR, risk ratio.
*CIs determined using the standard deviation estimated from 500 nonparametric bootstrap resamples.
†Standardized for patient age, sex, body mass index, hypertension, diabetes mellitus, hyperlipidemia, peripheral vascular disease, chronic kidney disease, smoking status, previous
percutaneous coronary intervention, previous coronary artery bypass grafting, and whether aspirin, statins, or beta blockers were prescribed at discharge.
‡Readmission diagnosis of myocardial infarction, congestive heart failure, cerebrovascular accident, cardiac arrhythmia, cardiac device complication, or structural heart abnormality.
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medication compliance. It is likely that some patients may
have been misclassiﬁed as being on more guideline-directed
cardiovascular medications than they were, but this misclas-
siﬁcation is expected to be the same across types of MI.
In addition, mortality data were obtained from the North
Carolina State Center for Health Statistics. The Center for
Health Statistics was not allowed to release data on deaths
that occurred out of state, which constituted about 1.5% of all
deaths for the calendar years of the study. This is comparable
to the data obtained from the Social Security Death Index,
which has overall accuracy of 95% and has been found to be
even more accurate in older individuals.25 We were also
unable to categorize postdischarge mortality into cardiovas-
cular or noncardiovascular causes, and readmission data were
restricted to the data available from our institution; therefore,
we may have missed any rehospitalizations that occurred at
other institutions.
We were also limited in the analysis we could conduct on
30-day readmission because of a low number of readmissions,
despite having causes for readmission. Moreover, although
we observed a lower incidence of readmission both before
and after weighing, we were underpowered to detect a
signiﬁcant difference in our analyses, which controlled for
confounding. The adjudication of type 1 versus type 2 MI was
performed by a single reviewer (S.A.) who was blinded to
outcomes using a prespeciﬁed criterion. In the setting of
doubt, the cases were discussed with a second reviewer (P.K.)
to reach a consensus on type 1 versus type 2 MI. The
adjudication by a single reviewer only was due to limitation in
resources and funding, and we understand that this approach
may lead to observational biases in which the ascertainment
of type 1 versus type 2 MI could be inﬂuenced by a reviewer’s
clinical beliefs and biases. Nevertheless, because the reviewer
used a prespeciﬁed criterion, we expect that bias would have
been minimized.
Finally, as with all analyses, there is the potential for
unmeasured confounding.
Conclusions
The NSTEMI metrics at our institution are signiﬁcantly
affected by type 2 MI patients. Despite representing only
25% of all NSTEMI patients, type 2 MI patients represent
>50% of all inpatient NSTEMI deaths, with the majority due to
noncardiovascular causes. Furthermore, these patients are
discharged on medications that are part of ACS quality
measures at a lower rate than type 1 MI patients. Interest-
ingly, patients with type 2 MI had lower readmission rates.
Consequently, it is important to recognize that type 2 MI
patients have distinct etiologies, are often managed differ-
ently, and have signiﬁcantly different prognoses compared
with patients with type 1 MI. Moving forward, it seems
prudent to categorize type 2 MI patients separately, instead of
under the general umbrella of NSTEMI, and to exclude these
patients from acute MI quality metrics. A multicenter study
with a larger sample size is needed to conﬁrm our ﬁndings
and to better understand how we can improve outcomes in
this high-risk population.
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